Complete response to brentuximab vedotin in a transplant-naïve patient with relapsed CD30-positive nodular lymphocyte-predominant Hodgkin lymphoma.

644.8. Schulz H, Rehwald U, Morschhauser F, et al. Rituximab in relapsed lympho-cyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by theGerman Hodgkin Lymphoma Study Group (GHSG). Blood. 2008;111:109-111.9. Advani RH, Horning SJ, Hoppe RT, et al. Frontline therapy of nodularlymphocyte predominant Hodgkin lymphoma with rituximab: the StanfordUniversity experience. Blood (ASH Annual Meeting Abstracts). 2011;118:Abstract 2686.10. Eichenauer DA, Fuchs M, Pluetschow A, et al. Phase 2 study of ritux-imab in newly diagnosed stage IA nodular lymphocyte-predominant Hodg-kin lymphoma: a report from the German Hodgkin Study Group. Blood.2011;118:4363-4365.11. Fanale MA, Lai CM, McLaughlin P, et al. Outcomes of nodular lymphocytepredominant Hodgkin’s lymphoma (NLPHL) patients treated with R-CHOP.Blood (ASH Annual Meeting Abstracts). 2010;116: Abstract 2812.12. Younes A, Bartlett NL, Leonard JP, et al. Brentuximab vedotin (SGN-35) forrelapsed CD30-positive lymphomas. N Engl J Med. 2010;363:1812-1821.13. Younes A, Gopal AK, Smith SE, et al. Results of a pivotal phase II study ofbrentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma.J Clin Oncol. 2012;30:2183-2189.14. ClinicalTrials.gov. A study of brentuximab vedotin in relapsed or refractoryCD30-positive non-Hodgkin lymphoma. http://www.clinicaltrials.gov/ct2/show/ NCT01421667. Identifier: NCT01421667.15. Jacobsen ED, Advani RH, Oki Y, et al. A phase 2 study of brentuximab vedotin in patients with relapsed or refractory CD30-positive non-Hodgkin lymphomas: interim results. Blood (ASH Annual Meeting Abstracts). 2012;120: Abstract 2746.